American biotechnology company

Moderna is an American biotechnology company based in Cambridge, Massachusetts. They focus on drug discovery and development, and vaccine technologies based on messenger RNA.[1]

As of November 2020, Moderna was valued at $35 billion, and while none of its drugs had been approved, its COVID-19 vaccine candidate was close to being authorized for mass use.[2]

In 2023 it is to build a centre in Harwell, Oxfordshire, to produce vaccines for Covid, flu and respiratory syncytial virus.[3]


  1. Catherine Shaffer (December 6, 2013). "Moderna Makes Entrance with $40M Round for mRNA Work". BioWorld. Archived from the original on November 16, 2020. Retrieved Dec 11, 2013.
  2. Kuznia, Robert; Polglase, Katie; Mezzofiore, Gianluca (1 May 2020). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN Investigates. Archived from the original on 16 November 2020. Retrieved 1 May 2020.
  3. "Moderna to build £150m vaccine centre in UK after NHS deal". Sunday Times. 5 March 2023. Archived from the original on 5 March 2023. Retrieved 8 March 2023.{{cite news}}: CS1 maint: bot: original URL status unknown (link)